Longitudinal profile of antibodies against SARS‐coronavirus in SARS patients and their clinical significance
Identifieur interne : 000520 ( Istex/Corpus ); précédent : 000519; suivant : 000521Longitudinal profile of antibodies against SARS‐coronavirus in SARS patients and their clinical significance
Auteurs : Hongying Mo ; Guangqiao Zeng ; Xiaolan Ren ; Hui Li ; Changwen Ke ; Yaxia Tan ; Chaoda Cai ; Kefang Lai ; Rongchang Chen ; Moira Chan-Yeung ; Nanshan ZhongSource :
- Respirology [ 1323-7799 ] ; 2006-01.
English descriptors
- Teeft :
- Antibodies titres, Antibody, Antibody neutralization test, Antibody response, Antibody titres, Assay, Blood samples, British columbia, Convalescent, Convalescent patients, Convalescent sera, Coronavirus, Elisa, Guangdong province, Guangzhou, Guangzhou institute, Indirect assay, Neutralization, Neutralization test, Neutralizing, Neutralizing antibodies, Novel coronavirus, Respiratory disease, Respiratory diseases, Respiratory syndrome, Rinsing buffer, Sars, Sars coronavirus, Sars patients, Serial sera, Serum antibodies, Serum samples, Similar results, Syndrome, Titre, Vero cells, Virus neutralization test, World health organization.
Abstract
Background: Severe acute respiratory syndrome (SARS) is a newly discovered disease caused by a novel coronavirus. The present study studied the longitudinal profile of antibodies against SARS‐coronavirus (SARS‐CoV) in SARS patients and evaluated the clinical significance of these antibodies. Methods: Two methods, ELISA and indirect immunofluorescent assay, were used for the detection of the anti‐SARS‐CoV IgG and IgM in 335 serial sera from 98 SARS patients. In 18 patients, serum antibody profiles were investigated and antibody neutralization tests were performed from 7 to 720 days after the onset of symptoms. Results: The ratios of positive IgG/IgM by ELISA were 0/0, 45.4/39.4, 88.6/71.4, 96/88, 100/48.6, 100/30.9, 100/17.1, 100/0 per cent, respectively, on 1–7, 8–14, 15–21, 22–28, 29–60, 61–90, 91–180 and 181–720 days after the onset of symptoms. Antibodies were not detected within the first 7 days of illness, but IgG titre increased dramatically on day 15, reaching a peak on day 60, and remained high until day 180 from when it declined gradually until day 720. IgM was detected on day 15 and rapidly reached a peak, then declined gradually until it was undetectable on day 180. Neutralizing viral antibodies were demonstrated in the convalescence sera from SARS patients. Conclusion: The persistence of detectable IgG antibodies and neutralizing viral antibodies for up to 720 days suggest that SARS patients may be protected from recurrent SARS‐CoV infection for up to 2 years.
Url:
DOI: 10.1111/j.1440-1843.2006.00783.x
Links to Exploration step
ISTEX:15DD49E0ED3C4B260E52012856E849161EB2D3A8Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Longitudinal profile of antibodies against SARS‐coronavirus in SARS patients and their clinical significance</title><author><name sortKey="Mo, Hongying" sort="Mo, Hongying" uniqKey="Mo H" first="Hongying" last="Mo">Hongying Mo</name><affiliation><mods:affiliation>Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical College,</mods:affiliation></affiliation></author><author><name sortKey="Zeng, Guangqiao" sort="Zeng, Guangqiao" uniqKey="Zeng G" first="Guangqiao" last="Zeng">Guangqiao Zeng</name><affiliation><mods:affiliation>Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical College,</mods:affiliation></affiliation></author><author><name sortKey="Ren, Xiaolan" sort="Ren, Xiaolan" uniqKey="Ren X" first="Xiaolan" last="Ren">Xiaolan Ren</name><affiliation><mods:affiliation>Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical College,</mods:affiliation></affiliation></author><author><name sortKey="Li, Hui" sort="Li, Hui" uniqKey="Li H" first="Hui" last="Li">Hui Li</name><affiliation><mods:affiliation>Center for Disease Prevent and Control of Guangdong Province, Guangzhou, China, and</mods:affiliation></affiliation></author><author><name sortKey="Ke, Changwen" sort="Ke, Changwen" uniqKey="Ke C" first="Changwen" last="Ke">Changwen Ke</name><affiliation><mods:affiliation>Center for Disease Prevent and Control of Guangdong Province, Guangzhou, China, and</mods:affiliation></affiliation></author><author><name sortKey="Tan, Yaxia" sort="Tan, Yaxia" uniqKey="Tan Y" first="Yaxia" last="Tan">Yaxia Tan</name><affiliation><mods:affiliation>Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical College,</mods:affiliation></affiliation></author><author><name sortKey="Cai, Chaoda" sort="Cai, Chaoda" uniqKey="Cai C" first="Chaoda" last="Cai">Chaoda Cai</name><affiliation><mods:affiliation>Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical College,</mods:affiliation></affiliation></author><author><name sortKey="Lai, Kefang" sort="Lai, Kefang" uniqKey="Lai K" first="Kefang" last="Lai">Kefang Lai</name><affiliation><mods:affiliation>Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical College,</mods:affiliation></affiliation></author><author><name sortKey="Chen, Rongchang" sort="Chen, Rongchang" uniqKey="Chen R" first="Rongchang" last="Chen">Rongchang Chen</name><affiliation><mods:affiliation>Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical College,</mods:affiliation></affiliation></author><author><name sortKey="Chan Eung, Moira" sort="Chan Eung, Moira" uniqKey="Chan Eung M" first="Moira" last="Chan-Yeung">Moira Chan-Yeung</name><affiliation><mods:affiliation>Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada</mods:affiliation></affiliation></author><author><name sortKey="Zhong, Nanshan" sort="Zhong, Nanshan" uniqKey="Zhong N" first="Nanshan" last="Zhong">Nanshan Zhong</name><affiliation><mods:affiliation>Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical College,</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: nanshan@vip.163.com</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:15DD49E0ED3C4B260E52012856E849161EB2D3A8</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1111/j.1440-1843.2006.00783.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-JTPM1CPK-3/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000520</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000520</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Longitudinal profile of antibodies against SARS‐coronavirus in SARS patients and their clinical significance</title><author><name sortKey="Mo, Hongying" sort="Mo, Hongying" uniqKey="Mo H" first="Hongying" last="Mo">Hongying Mo</name><affiliation><mods:affiliation>Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical College,</mods:affiliation></affiliation></author><author><name sortKey="Zeng, Guangqiao" sort="Zeng, Guangqiao" uniqKey="Zeng G" first="Guangqiao" last="Zeng">Guangqiao Zeng</name><affiliation><mods:affiliation>Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical College,</mods:affiliation></affiliation></author><author><name sortKey="Ren, Xiaolan" sort="Ren, Xiaolan" uniqKey="Ren X" first="Xiaolan" last="Ren">Xiaolan Ren</name><affiliation><mods:affiliation>Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical College,</mods:affiliation></affiliation></author><author><name sortKey="Li, Hui" sort="Li, Hui" uniqKey="Li H" first="Hui" last="Li">Hui Li</name><affiliation><mods:affiliation>Center for Disease Prevent and Control of Guangdong Province, Guangzhou, China, and</mods:affiliation></affiliation></author><author><name sortKey="Ke, Changwen" sort="Ke, Changwen" uniqKey="Ke C" first="Changwen" last="Ke">Changwen Ke</name><affiliation><mods:affiliation>Center for Disease Prevent and Control of Guangdong Province, Guangzhou, China, and</mods:affiliation></affiliation></author><author><name sortKey="Tan, Yaxia" sort="Tan, Yaxia" uniqKey="Tan Y" first="Yaxia" last="Tan">Yaxia Tan</name><affiliation><mods:affiliation>Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical College,</mods:affiliation></affiliation></author><author><name sortKey="Cai, Chaoda" sort="Cai, Chaoda" uniqKey="Cai C" first="Chaoda" last="Cai">Chaoda Cai</name><affiliation><mods:affiliation>Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical College,</mods:affiliation></affiliation></author><author><name sortKey="Lai, Kefang" sort="Lai, Kefang" uniqKey="Lai K" first="Kefang" last="Lai">Kefang Lai</name><affiliation><mods:affiliation>Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical College,</mods:affiliation></affiliation></author><author><name sortKey="Chen, Rongchang" sort="Chen, Rongchang" uniqKey="Chen R" first="Rongchang" last="Chen">Rongchang Chen</name><affiliation><mods:affiliation>Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical College,</mods:affiliation></affiliation></author><author><name sortKey="Chan Eung, Moira" sort="Chan Eung, Moira" uniqKey="Chan Eung M" first="Moira" last="Chan-Yeung">Moira Chan-Yeung</name><affiliation><mods:affiliation>Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada</mods:affiliation></affiliation></author><author><name sortKey="Zhong, Nanshan" sort="Zhong, Nanshan" uniqKey="Zhong N" first="Nanshan" last="Zhong">Nanshan Zhong</name><affiliation><mods:affiliation>Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical College,</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: nanshan@vip.163.com</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Respirology</title><title level="j" type="alt">RESPIROLOGY</title><idno type="ISSN">1323-7799</idno><idno type="eISSN">1440-1843</idno><imprint><biblScope unit="vol">11</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="49">49</biblScope><biblScope unit="page" to="53">53</biblScope><biblScope unit="page-count">5</biblScope><publisher>Blackwell Science Pty</publisher><pubPlace>Melbourne, Australia</pubPlace><date type="published" when="2006-01">2006-01</date></imprint><idno type="ISSN">1323-7799</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1323-7799</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Antibodies titres</term><term>Antibody</term><term>Antibody neutralization test</term><term>Antibody response</term><term>Antibody titres</term><term>Assay</term><term>Blood samples</term><term>British columbia</term><term>Convalescent</term><term>Convalescent patients</term><term>Convalescent sera</term><term>Coronavirus</term><term>Elisa</term><term>Guangdong province</term><term>Guangzhou</term><term>Guangzhou institute</term><term>Indirect assay</term><term>Neutralization</term><term>Neutralization test</term><term>Neutralizing</term><term>Neutralizing antibodies</term><term>Novel coronavirus</term><term>Respiratory disease</term><term>Respiratory diseases</term><term>Respiratory syndrome</term><term>Rinsing buffer</term><term>Sars</term><term>Sars coronavirus</term><term>Sars patients</term><term>Serial sera</term><term>Serum antibodies</term><term>Serum samples</term><term>Similar results</term><term>Syndrome</term><term>Titre</term><term>Vero cells</term><term>Virus neutralization test</term><term>World health organization</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background: Severe acute respiratory syndrome (SARS) is a newly discovered disease caused by a novel coronavirus. The present study studied the longitudinal profile of antibodies against SARS‐coronavirus (SARS‐CoV) in SARS patients and evaluated the clinical significance of these antibodies. Methods: Two methods, ELISA and indirect immunofluorescent assay, were used for the detection of the anti‐SARS‐CoV IgG and IgM in 335 serial sera from 98 SARS patients. In 18 patients, serum antibody profiles were investigated and antibody neutralization tests were performed from 7 to 720 days after the onset of symptoms. Results: The ratios of positive IgG/IgM by ELISA were 0/0, 45.4/39.4, 88.6/71.4, 96/88, 100/48.6, 100/30.9, 100/17.1, 100/0 per cent, respectively, on 1–7, 8–14, 15–21, 22–28, 29–60, 61–90, 91–180 and 181–720 days after the onset of symptoms. Antibodies were not detected within the first 7 days of illness, but IgG titre increased dramatically on day 15, reaching a peak on day 60, and remained high until day 180 from when it declined gradually until day 720. IgM was detected on day 15 and rapidly reached a peak, then declined gradually until it was undetectable on day 180. Neutralizing viral antibodies were demonstrated in the convalescence sera from SARS patients. Conclusion: The persistence of detectable IgG antibodies and neutralizing viral antibodies for up to 720 days suggest that SARS patients may be protected from recurrent SARS‐CoV infection for up to 2 years.</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>sars</json:string><json:string>sars patients</json:string><json:string>elisa</json:string><json:string>neutralizing</json:string><json:string>coronavirus</json:string><json:string>guangzhou</json:string><json:string>respiratory syndrome</json:string><json:string>convalescent</json:string><json:string>neutralizing antibodies</json:string><json:string>indirect assay</json:string><json:string>assay</json:string><json:string>novel coronavirus</json:string><json:string>guangzhou institute</json:string><json:string>blood samples</json:string><json:string>antibodies titres</json:string><json:string>serum samples</json:string><json:string>syndrome</json:string><json:string>neutralization</json:string><json:string>antibody</json:string><json:string>titre</json:string><json:string>guangdong province</json:string><json:string>virus neutralization test</json:string><json:string>respiratory diseases</json:string><json:string>serial sera</json:string><json:string>serum antibodies</json:string><json:string>british columbia</json:string><json:string>rinsing buffer</json:string><json:string>vero cells</json:string><json:string>sars coronavirus</json:string><json:string>neutralization test</json:string><json:string>antibody titres</json:string><json:string>similar results</json:string><json:string>antibody neutralization test</json:string><json:string>convalescent sera</json:string><json:string>convalescent patients</json:string><json:string>respiratory disease</json:string><json:string>world health organization</json:string><json:string>antibody response</json:string></teeft></keywords><author><json:item><name>Hongying MO</name><affiliations><json:string>Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical College,</json:string></affiliations></json:item><json:item><name>Guangqiao ZENG</name><affiliations><json:string>Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical College,</json:string></affiliations></json:item><json:item><name>Xiaolan REN</name><affiliations><json:string>Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical College,</json:string></affiliations></json:item><json:item><name>Hui LI</name><affiliations><json:string>Center for Disease Prevent and Control of Guangdong Province, Guangzhou, China, and</json:string></affiliations></json:item><json:item><name>Changwen KE</name><affiliations><json:string>Center for Disease Prevent and Control of Guangdong Province, Guangzhou, China, and</json:string></affiliations></json:item><json:item><name>Yaxia TAN</name><affiliations><json:string>Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical College,</json:string></affiliations></json:item><json:item><name>Chaoda CAI</name><affiliations><json:string>Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical College,</json:string></affiliations></json:item><json:item><name>Kefang LAI</name><affiliations><json:string>Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical College,</json:string></affiliations></json:item><json:item><name>Rongchang CHEN</name><affiliations><json:string>Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical College,</json:string></affiliations></json:item><json:item><name>Moira CHAN‐YEUNG</name><affiliations><json:string>Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada</json:string></affiliations></json:item><json:item><name>Nanshan ZHONG</name><affiliations><json:string>Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical College,</json:string><json:string>E-mail: nanshan@vip.163.com</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>antibody</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>antibody neutralization test</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>severe acute respiratory syndrome</value></json:item></subject><articleId><json:string>RESP783</json:string></articleId><arkIstex>ark:/67375/WNG-JTPM1CPK-3</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>Background: Severe acute respiratory syndrome (SARS) is a newly discovered disease caused by a novel coronavirus. The present study studied the longitudinal profile of antibodies against SARS‐coronavirus (SARS‐CoV) in SARS patients and evaluated the clinical significance of these antibodies. Methods: Two methods, ELISA and indirect immunofluorescent assay, were used for the detection of the anti‐SARS‐CoV IgG and IgM in 335 serial sera from 98 SARS patients. In 18 patients, serum antibody profiles were investigated and antibody neutralization tests were performed from 7 to 720 days after the onset of symptoms. Results: The ratios of positive IgG/IgM by ELISA were 0/0, 45.4/39.4, 88.6/71.4, 96/88, 100/48.6, 100/30.9, 100/17.1, 100/0 per cent, respectively, on 1–7, 8–14, 15–21, 22–28, 29–60, 61–90, 91–180 and 181–720 days after the onset of symptoms. Antibodies were not detected within the first 7 days of illness, but IgG titre increased dramatically on day 15, reaching a peak on day 60, and remained high until day 180 from when it declined gradually until day 720. IgM was detected on day 15 and rapidly reached a peak, then declined gradually until it was undetectable on day 180. Neutralizing viral antibodies were demonstrated in the convalescence sera from SARS patients. Conclusion: The persistence of detectable IgG antibodies and neutralizing viral antibodies for up to 720 days suggest that SARS patients may be protected from recurrent SARS‐CoV infection for up to 2 years.</abstract><qualityIndicators><refBibsNative>true</refBibsNative><abstractWordCount>225</abstractWordCount><abstractCharCount>1500</abstractCharCount><keywordCount>3</keywordCount><score>7.758</score><pdfWordCount>3058</pdfWordCount><pdfCharCount>18622</pdfCharCount><pdfVersion>1.4</pdfVersion><pdfPageCount>5</pdfPageCount><pdfPageSize>595 x 780 pts</pdfPageSize><pdfWordsPerPage>612</pdfWordsPerPage><pdfText>true</pdfText></qualityIndicators><title>Longitudinal profile of antibodies against SARS‐coronavirus in SARS patients and their clinical significance</title><pmid><json:string>16423201</json:string></pmid><genre><json:string>article</json:string></genre><host><title>Respirology</title><language><json:string>unknown</json:string></language><doi><json:string>10.1111/(ISSN)1440-1843</json:string></doi><issn><json:string>1323-7799</json:string></issn><eissn><json:string>1440-1843</json:string></eissn><publisherId><json:string>RESP</json:string></publisherId><volume>11</volume><issue>1</issue><pages><first>49</first><last>53</last><total>5</total></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>Between December 2002 and June 2003</json:string><json:string>2006</json:string><json:string>2003</json:string></date><geogName></geogName><orgName><json:string>The Chinese SARS Molecular Epidemiology Consortium.</json:string><json:string>Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada Longitudinal</json:string><json:string>World Health Organization.</json:string><json:string>Beijing Institute of Microbiology and Epidemiology</json:string><json:string>Guangzhou Institute of Respiratory Disease</json:string><json:string>Biotech</json:string><json:string>Hospital of Guangzhou Medical College</json:string><json:string>National High Technology Research and Development Program of China</json:string><json:string>Committee of Guangzhou</json:string><json:string>World Health Organization</json:string><json:string>Guangzhou Institute of Respiratory Diseases</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Studies</json:string><json:string>IgG</json:string></persName><placeName><json:string>IL</json:string><json:string>Beijing</json:string><json:string>UK</json:string><json:string>Poole</json:string><json:string>China</json:string><json:string>USA</json:string><json:string>Chicago</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>Shi et al.</json:string><json:string>Woo et al.</json:string><json:string>Mo et al.</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/WNG-JTPM1CPK-3</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - respiratory system</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - respiratory system</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Pulmonary and Respiratory Medicine</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>2006</publicationDate><copyrightDate>2006</copyrightDate><doi><json:string>10.1111/j.1440-1843.2006.00783.x</json:string></doi><id>15DD49E0ED3C4B260E52012856E849161EB2D3A8</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-JTPM1CPK-3/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-JTPM1CPK-3/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/WNG-JTPM1CPK-3/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Longitudinal profile of antibodies against SARS‐coronavirus in SARS patients and their clinical significance</title><title level="a" type="short">Antibodies against SARS‐coronavirus</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Science Pty</publisher><pubPlace>Melbourne, Australia</pubPlace><date type="published" when="2006-01"></date></publicationStmt><notesStmt><note type="content-type" subtype="article" source="article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="article"><analytic><title level="a" type="main">Longitudinal profile of antibodies against SARS‐coronavirus in SARS patients and their clinical significance</title><title level="a" type="short">Antibodies against SARS‐coronavirus</title><author xml:id="author-0000"><persName><forename type="first">Hongying</forename><surname>MO</surname></persName><affiliation><orgName type="institution">Guangzhou Institute of Respiratory Disease</orgName><orgName type="institution">First Affiliated Hospital of Guangzhou Medical College</orgName></affiliation></author><author xml:id="author-0001"><persName><forename type="first">Guangqiao</forename><surname>ZENG</surname></persName><affiliation><orgName type="institution">Guangzhou Institute of Respiratory Disease</orgName><orgName type="institution">First Affiliated Hospital of Guangzhou Medical College</orgName></affiliation></author><author xml:id="author-0002"><persName><forename type="first">Xiaolan</forename><surname>REN</surname></persName><affiliation><orgName type="institution">Guangzhou Institute of Respiratory Disease</orgName><orgName type="institution">First Affiliated Hospital of Guangzhou Medical College</orgName></affiliation></author><author xml:id="author-0003"><persName><forename type="first">Hui</forename><surname>LI</surname></persName><affiliation><orgName type="institution">Center for Disease Prevent and Control of Guangdong Province</orgName><address><addrLine>Guangzhou</addrLine><addrLine>China, and</addrLine><country key="CN" xml:lang="en">CHINA</country></address></affiliation></author><author xml:id="author-0004"><persName><forename type="first">Changwen</forename><surname>KE</surname></persName><affiliation><orgName type="institution">Center for Disease Prevent and Control of Guangdong Province</orgName><address><addrLine>Guangzhou</addrLine><addrLine>China, and</addrLine><country key="CN" xml:lang="en">CHINA</country></address></affiliation></author><author xml:id="author-0005"><persName><forename type="first">Yaxia</forename><surname>TAN</surname></persName><affiliation><orgName type="institution">Guangzhou Institute of Respiratory Disease</orgName><orgName type="institution">First Affiliated Hospital of Guangzhou Medical College</orgName></affiliation></author><author xml:id="author-0006"><persName><forename type="first">Chaoda</forename><surname>CAI</surname></persName><affiliation><orgName type="institution">Guangzhou Institute of Respiratory Disease</orgName><orgName type="institution">First Affiliated Hospital of Guangzhou Medical College</orgName></affiliation></author><author xml:id="author-0007"><persName><forename type="first">Kefang</forename><surname>LAI</surname></persName><affiliation><orgName type="institution">Guangzhou Institute of Respiratory Disease</orgName><orgName type="institution">First Affiliated Hospital of Guangzhou Medical College</orgName></affiliation></author><author xml:id="author-0008"><persName><forename type="first">Rongchang</forename><surname>CHEN</surname></persName><affiliation><orgName type="institution">Guangzhou Institute of Respiratory Disease</orgName><orgName type="institution">First Affiliated Hospital of Guangzhou Medical College</orgName></affiliation></author><author xml:id="author-0009"><persName><forename type="first">Moira</forename><surname>CHAN‐YEUNG</surname></persName><affiliation><orgName type="division">Department of Medicine</orgName><orgName type="institution">University of British Columbia</orgName><address><addrLine>Vancouver</addrLine><addrLine>British Columbia, Canada</addrLine><country key="CA" xml:lang="en">CANADA</country></address></affiliation></author><author xml:id="author-0010" role="corresp"><persName><forename type="first">Nanshan</forename><surname>ZHONG</surname></persName><affiliation><orgName type="institution">Guangzhou Institute of Respiratory Disease</orgName><orgName type="institution">First Affiliated Hospital of Guangzhou Medical College</orgName></affiliation></author><idno type="istex">15DD49E0ED3C4B260E52012856E849161EB2D3A8</idno><idno type="ark">ark:/67375/WNG-JTPM1CPK-3</idno><idno type="DOI">10.1111/j.1440-1843.2006.00783.x</idno><idno type="unit">RESP783</idno><idno type="toTypesetVersion">file:RESP.RESP783.pdf</idno></analytic><monogr><title level="j" type="main">Respirology</title><title level="j" type="alt">RESPIROLOGY</title><idno type="pISSN">1323-7799</idno><idno type="eISSN">1440-1843</idno><idno type="book-DOI">10.1111/(ISSN)1440-1843</idno><idno type="book-part-DOI">10.1111/res.2006.11.issue-1</idno><idno type="product">RESP</idno><idno type="publisherDivision">ST</idno><imprint><biblScope unit="vol">11</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="49">49</biblScope><biblScope unit="page" to="53">53</biblScope><biblScope unit="page-count">5</biblScope><publisher>Blackwell Science Pty</publisher><pubPlace>Melbourne, Australia</pubPlace><date type="published" when="2006-01"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-20"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract xml:lang="en" style="main"><p><hi rend="bold">Background: </hi> Severe acute respiratory syndrome (SARS) is a newly discovered disease caused by a novel coronavirus. The present study studied the longitudinal profile of antibodies against SARS‐coronavirus (SARS‐CoV) in SARS patients and evaluated the clinical significance of these antibodies.</p><p><hi rend="bold">Methods: </hi> Two methods, ELISA and indirect immunofluorescent assay, were used for the detection of the anti‐SARS‐CoV IgG and IgM in 335 serial sera from 98 SARS patients. In 18 patients, serum antibody profiles were investigated and antibody neutralization tests were performed from 7 to 720 days after the onset of symptoms.</p><p><hi rend="bold">Results: </hi> The ratios of positive IgG/IgM by ELISA were 0/0, 45.4/39.4, 88.6/71.4, 96/88, 100/48.6, 100/30.9, 100/17.1, 100/0 per cent, respectively, on 1–7, 8–14, 15–21, 22–28, 29–60, 61–90, 91–180 and 181–720 days after the onset of symptoms. Antibodies were not detected within the first 7 days of illness, but IgG titre increased dramatically on day 15, reaching a peak on day 60, and remained high until day 180 from when it declined gradually until day 720. IgM was detected on day 15 and rapidly reached a peak, then declined gradually until it was undetectable on day 180. Neutralizing viral antibodies were demonstrated in the convalescence sera from SARS patients.</p><p><hi rend="bold">Conclusion: </hi> The persistence of detectable IgG antibodies and neutralizing viral antibodies for up to 720 days suggest that SARS patients may be protected from recurrent SARS‐CoV infection for up to 2 years.</p></abstract><textClass><keywords xml:lang="en"><term xml:id="k1">antibody</term><term xml:id="k2">antibody neutralization test</term><term xml:id="k3">severe acute respiratory syndrome</term></keywords><keywords rend="tocHeading1"><term>ORIGINAL ARTICLES</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc><revisionDesc><change when="2019-12-20" who="#istex" xml:id="pub2tei">formatting</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-JTPM1CPK-3/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Science Pty</publisherName><publisherLoc>Melbourne, Australia</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1440-1843</doi><issn type="print">1323-7799</issn><issn type="electronic">1440-1843</issn><idGroup><id type="product" value="RESP"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="RESPIROLOGY">Respirology</title></titleGroup></publicationMeta><publicationMeta level="part" position="01001"><doi origin="wiley">10.1111/res.2006.11.issue-1</doi><numberingGroup><numbering type="journalVolume" number="11">11</numbering><numbering type="journalIssue" number="1">1</numbering></numberingGroup><coverDate startDate="2006-01">January 2006</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="9" status="forIssue"><doi origin="wiley">10.1111/j.1440-1843.2006.00783.x</doi><idGroup><id type="unit" value="RESP783"></id></idGroup><countGroup><count type="pageTotal" number="5"></count></countGroup><titleGroup><title type="tocHeading1">ORIGINAL ARTICLES</title></titleGroup><eventGroup><event type="firstOnline" date="2006-01-12"></event><event type="publishedOnlineFinalForm" date="2006-01-12"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-02-28"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-08"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-11-03"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="49">49</numbering><numbering type="pageLast" number="53">53</numbering></numberingGroup><correspondenceTo>Nanshan Zhong, Guangzhou Institute of Respiratory Disease, 151, Yanjiang Road, Guangzhou, China. Email: <email>nanshan@vip.163.com</email></correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:RESP.RESP783.pdf"></link></linkGroup></publicationMeta><contentMeta><unparsedEditorialHistory>Received 10 January 2005; invited to revise 10 April 2005; revised 26 July 2005; accepted 27 July 2005 (Associate Editor: Kenneth Tsang).</unparsedEditorialHistory><countGroup><count type="figureTotal" number="2"></count><count type="tableTotal" number="1"></count><count type="formulaTotal" number="0"></count><count type="referenceTotal" number="16"></count><count type="wordTotal" number="3515"></count><count type="linksPubMed" number="0"></count><count type="linksCrossRef" number="0"></count></countGroup><titleGroup><title type="main">Longitudinal profile of antibodies against SARS‐coronavirus in SARS patients and their clinical significance</title><title type="shortAuthors">H Mo <i>et al.</i></title><title type="short">Antibodies against SARS‐coronavirus</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1"><personName><givenNames>Hongying</givenNames><familyName>MO</familyName></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a1"><personName><givenNames>Guangqiao</givenNames><familyName>ZENG</familyName></personName></creator><creator creatorRole="author" xml:id="cr3" affiliationRef="#a1"><personName><givenNames>Xiaolan</givenNames><familyName>REN</familyName></personName></creator><creator creatorRole="author" xml:id="cr4" affiliationRef="#a2"><personName><givenNames>Hui</givenNames><familyName>LI</familyName></personName></creator><creator creatorRole="author" xml:id="cr5" affiliationRef="#a2"><personName><givenNames>Changwen</givenNames><familyName>KE</familyName></personName></creator><creator creatorRole="author" xml:id="cr6" affiliationRef="#a1"><personName><givenNames>Yaxia</givenNames><familyName>TAN</familyName></personName></creator><creator creatorRole="author" xml:id="cr7" affiliationRef="#a1"><personName><givenNames>Chaoda</givenNames><familyName>CAI</familyName></personName></creator><creator creatorRole="author" xml:id="cr8" affiliationRef="#a1"><personName><givenNames>Kefang</givenNames><familyName>LAI</familyName></personName></creator><creator creatorRole="author" xml:id="cr9" affiliationRef="#a1"><personName><givenNames>Rongchang</givenNames><familyName>CHEN</familyName></personName></creator><creator creatorRole="author" xml:id="cr10" affiliationRef="#a3"><personName><givenNames>Moira</givenNames><familyName>CHAN‐YEUNG</familyName></personName></creator><creator creatorRole="author" xml:id="cr11" affiliationRef="#a1" corresponding="yes"><personName><givenNames>Nanshan</givenNames><familyName>ZHONG</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1"><unparsedAffiliation>Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical College,</unparsedAffiliation></affiliation><affiliation xml:id="a2" countryCode="CN"><unparsedAffiliation>Center for Disease Prevent and Control of Guangdong Province, Guangzhou, China, and</unparsedAffiliation></affiliation><affiliation xml:id="a3" countryCode="CA"><unparsedAffiliation>Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">antibody</keyword><keyword xml:id="k2">antibody neutralization test</keyword><keyword xml:id="k3">severe acute respiratory syndrome</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><!--
Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance
MO HY, ZENG GQ, REN XL, LI H, KE CW, TAN YX, CAI CD, LAI KF, CHEN RC, CHAN-YEUNG M, ZHONG NS. Respirology 2006; 11: 49–53
--><p><b>Background: </b> Severe acute respiratory syndrome (SARS) is a newly discovered disease caused by a novel coronavirus. The present study studied the longitudinal profile of antibodies against SARS‐coronavirus (SARS‐CoV) in SARS patients and evaluated the clinical significance of these antibodies.</p><p><b>Methods: </b> Two methods, ELISA and indirect immunofluorescent assay, were used for the detection of the anti‐SARS‐CoV IgG and IgM in 335 serial sera from 98 SARS patients. In 18 patients, serum antibody profiles were investigated and antibody neutralization tests were performed from 7 to 720 days after the onset of symptoms.</p><p><b>Results: </b> The ratios of positive IgG/IgM by ELISA were 0/0, 45.4/39.4, 88.6/71.4, 96/88, 100/48.6, 100/30.9, 100/17.1, 100/0 per cent, respectively, on 1–7, 8–14, 15–21, 22–28, 29–60, 61–90, 91–180 and 181–720 days after the onset of symptoms. Antibodies were not detected within the first 7 days of illness, but IgG titre increased dramatically on day 15, reaching a peak on day 60, and remained high until day 180 from when it declined gradually until day 720. IgM was detected on day 15 and rapidly reached a peak, then declined gradually until it was undetectable on day 180. Neutralizing viral antibodies were demonstrated in the convalescence sera from SARS patients.</p><p><b>Conclusion: </b> The persistence of detectable IgG antibodies and neutralizing viral antibodies for up to 720 days suggest that SARS patients may be protected from recurrent SARS‐CoV infection for up to 2 years.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Longitudinal profile of antibodies against SARS‐coronavirus in SARS patients and their clinical significance</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Antibodies against SARS‐coronavirus</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Longitudinal profile of antibodies against SARS‐coronavirus in SARS patients and their clinical significance</title></titleInfo><name type="personal"><namePart type="given">Hongying</namePart><namePart type="family">MO</namePart><affiliation>Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical College,</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Guangqiao</namePart><namePart type="family">ZENG</namePart><affiliation>Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical College,</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Xiaolan</namePart><namePart type="family">REN</namePart><affiliation>Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical College,</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Hui</namePart><namePart type="family">LI</namePart><affiliation>Center for Disease Prevent and Control of Guangdong Province, Guangzhou, China, and</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Changwen</namePart><namePart type="family">KE</namePart><affiliation>Center for Disease Prevent and Control of Guangdong Province, Guangzhou, China, and</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Yaxia</namePart><namePart type="family">TAN</namePart><affiliation>Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical College,</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Chaoda</namePart><namePart type="family">CAI</namePart><affiliation>Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical College,</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Kefang</namePart><namePart type="family">LAI</namePart><affiliation>Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical College,</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Rongchang</namePart><namePart type="family">CHEN</namePart><affiliation>Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical College,</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Moira</namePart><namePart type="family">CHAN‐YEUNG</namePart><affiliation>Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Nanshan</namePart><namePart type="family">ZHONG</namePart><affiliation>Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical College,</affiliation><affiliation>E-mail: nanshan@vip.163.com</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</genre><originInfo><publisher>Blackwell Science Pty</publisher><place><placeTerm type="text">Melbourne, Australia</placeTerm></place><dateIssued encoding="w3cdtf">2006-01</dateIssued><edition>Received 10 January 2005; invited to revise 10 April 2005; revised 26 July 2005; accepted 27 July 2005 (Associate Editor: Kenneth Tsang).</edition><copyrightDate encoding="w3cdtf">2006</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><extent unit="figures">2</extent><extent unit="tables">1</extent><extent unit="formulas">0</extent><extent unit="references">16</extent><extent unit="linksCrossRef">0</extent><extent unit="words">3515</extent></physicalDescription><abstract lang="en">Background: Severe acute respiratory syndrome (SARS) is a newly discovered disease caused by a novel coronavirus. The present study studied the longitudinal profile of antibodies against SARS‐coronavirus (SARS‐CoV) in SARS patients and evaluated the clinical significance of these antibodies. Methods: Two methods, ELISA and indirect immunofluorescent assay, were used for the detection of the anti‐SARS‐CoV IgG and IgM in 335 serial sera from 98 SARS patients. In 18 patients, serum antibody profiles were investigated and antibody neutralization tests were performed from 7 to 720 days after the onset of symptoms. Results: The ratios of positive IgG/IgM by ELISA were 0/0, 45.4/39.4, 88.6/71.4, 96/88, 100/48.6, 100/30.9, 100/17.1, 100/0 per cent, respectively, on 1–7, 8–14, 15–21, 22–28, 29–60, 61–90, 91–180 and 181–720 days after the onset of symptoms. Antibodies were not detected within the first 7 days of illness, but IgG titre increased dramatically on day 15, reaching a peak on day 60, and remained high until day 180 from when it declined gradually until day 720. IgM was detected on day 15 and rapidly reached a peak, then declined gradually until it was undetectable on day 180. Neutralizing viral antibodies were demonstrated in the convalescence sera from SARS patients. Conclusion: The persistence of detectable IgG antibodies and neutralizing viral antibodies for up to 720 days suggest that SARS patients may be protected from recurrent SARS‐CoV infection for up to 2 years.</abstract><subject lang="en"><genre>keywords</genre><topic>antibody</topic><topic>antibody neutralization test</topic><topic>severe acute respiratory syndrome</topic></subject><relatedItem type="host"><titleInfo><title>Respirology</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><identifier type="ISSN">1323-7799</identifier><identifier type="eISSN">1440-1843</identifier><identifier type="DOI">10.1111/(ISSN)1440-1843</identifier><identifier type="PublisherID">RESP</identifier><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>49</start><end>53</end><total>5</total></extent></part></relatedItem><relatedItem type="references" displayLabel="cit2"><titleInfo><title>A cluster of cases of severe acute respiratory syndrome in Hong Kong</title></titleInfo><name type="personal"><namePart type="given">KW</namePart><namePart type="family">Tsang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PL</namePart><namePart type="family">Ho</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GC</namePart><namePart type="family">Ooi</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tsang KW, Ho PL, Ooi GC et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N. Engl. J. Med. 2003; 348: 1977–85.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>348</number></detail><extent unit="pages"><start>1977</start><end>85</end></extent></part><relatedItem type="host"><titleInfo><title>N. Engl. J. Med.</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>348</number></detail><extent unit="pages"><start>1977</start><end>85</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit3"><titleInfo><title>Clinical features and short‐term outcomes of 144 patients with SARS in the Greater Toronto area</title></titleInfo><name type="personal"><namePart type="given">CM</namePart><namePart type="family">Booth</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LM</namePart><namePart type="family">Matukas</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GA</namePart><namePart type="family">Tomlinson</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Booth CM, Matukas LM, Tomlinson GA et al. Clinical features and short‐term outcomes of 144 patients with SARS in the Greater Toronto area. JAMA 2003; 289: 2801–9.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>289</number></detail><extent unit="pages"><start>2801</start><end>9</end></extent></part><relatedItem type="host"><titleInfo><title>JAMA</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>289</number></detail><extent unit="pages"><start>2801</start><end>9</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit4"><titleInfo><title>World Health Organization.Summary of SARS Cases by Country from 1 November 2002 to 7 August 2003.World Health Organization, http://who.int/csr/sars/country/2003_08_15/en/. 11 November 2003.</title></titleInfo><name type="corporate"><namePart>World Health Organization.</namePart></name><note type="citation/reference">World Health Organization. Summary of SARS Cases by Country from 1 November 2002 to 7 August 2003. World Health Organization, http://who.int/csr/sars/country/2003_08_15/en/. 11 November 2003.</note><genre>book</genre><originInfo><publisher>World Health Organization</publisher></originInfo></relatedItem><relatedItem type="references" displayLabel="cit5"><titleInfo><title>Identification of a novel coronavirus in patients with severe acute respiratory syndrome</title></titleInfo><name type="personal"><namePart type="given">C</namePart><namePart type="family">Drosten</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Gunther</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W</namePart><namePart type="family">Preiser</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Drosten C, Gunther S, Preiser W et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 2003; 384: 1967–76.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>384</number></detail><extent unit="pages"><start>1967</start><end>76</end></extent></part><relatedItem type="host"><titleInfo><title>N. Engl. J. Med.</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>384</number></detail><extent unit="pages"><start>1967</start><end>76</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit6"><titleInfo><title>A novel coronavirus associated with severe acute respiratory syndrome</title></titleInfo><name type="personal"><namePart type="given">TG</namePart><namePart type="family">Ksiazek</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Erdman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CS</namePart><namePart type="family">Goldsmith</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ksiazek TG, Erdman D, Goldsmith CS et al. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 2003; 348: 1953–66.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>348</number></detail><extent unit="pages"><start>1953</start><end>66</end></extent></part><relatedItem type="host"><titleInfo><title>N. Engl. J. Med.</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>348</number></detail><extent unit="pages"><start>1953</start><end>66</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit7"><titleInfo><title>The genome sequence of the SARS‐associate coronavirus</title></titleInfo><name type="personal"><namePart type="given">MA</namePart><namePart type="family">Marra</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SJ</namePart><namePart type="family">Jones</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CR</namePart><namePart type="family">Astell</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Marra MA, Jones SJ, Astell CR et al. The genome sequence of the SARS‐associate coronavirus. Science 2003; 300: 1399–404.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>300</number></detail><extent unit="pages"><start>1399</start><end>404</end></extent></part><relatedItem type="host"><titleInfo><title>Science</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>300</number></detail><extent unit="pages"><start>1399</start><end>404</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit8"><titleInfo><title>Characterization of a novel coronavirus associated with severe acute respiratory syndrome</title></titleInfo><name type="personal"><namePart type="given">PA</namePart><namePart type="family">Rota</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MS</namePart><namePart type="family">Oberste</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SS</namePart><namePart type="family">Monroe</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rota PA, Oberste MS, Monroe SS et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003; 300: 1394–9.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>300</number></detail><extent unit="pages"><start>1394</start><end>9</end></extent></part><relatedItem type="host"><titleInfo><title>Science</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>300</number></detail><extent unit="pages"><start>1394</start><end>9</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit9"><titleInfo><title>Clinical progression and viral load in a community outbreak of coronavirus‐associated SARS pneumonia: a prospective study</title></titleInfo><name type="personal"><namePart type="given">JSM</namePart><namePart type="family">Peiris</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CM</namePart><namePart type="family">Chu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">VCC</namePart><namePart type="family">Cheng</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Peiris JSM, Chu CM, Cheng VCC et al. Clinical progression and viral load in a community outbreak of coronavirus‐associated SARS pneumonia: a prospective study. Lancet 2003; 361: 1767–72.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>361</number></detail><extent unit="pages"><start>1767</start><end>72</end></extent></part><relatedItem type="host"><titleInfo><title>Lancet</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>361</number></detail><extent unit="pages"><start>1767</start><end>72</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit10"><titleInfo><title>Profile of specific antibodies to the SARS‐associated coronavirus</title></titleInfo><name type="personal"><namePart type="given">G</namePart><namePart type="family">Li</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">X</namePart><namePart type="family">Chen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Xu</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Li G, Chen X, Xu A. Profile of specific antibodies to the SARS‐associated coronavirus. N. Engl. J. Med. 2003; 349: 508–9.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>349</number></detail><extent unit="pages"><start>508</start><end>9</end></extent></part><relatedItem type="host"><titleInfo><title>N. Engl. J. Med.</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>349</number></detail><extent unit="pages"><start>508</start><end>9</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit11"><titleInfo><title>Evaluation of WHO criteria for identifying patients with severe acute respiratory syndrome out of hospital: prospective observational study</title></titleInfo><name type="personal"><namePart type="given">TH</namePart><namePart type="family">Rainer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PA</namePart><namePart type="family">Cameron</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">DeVilliers</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rainer TH, Cameron PA, DeVilliers S et al. Evaluation of WHO criteria for identifying patients with severe acute respiratory syndrome out of hospital: prospective observational study. BMJ 2003; 326: 1354–8.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>326</number></detail><extent unit="pages"><start>1354</start><end>8</end></extent></part><relatedItem type="host"><titleInfo><title>BMJ</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>326</number></detail><extent unit="pages"><start>1354</start><end>8</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit12"><titleInfo><title>Antibody responses against SARS‐coronavirus and its nucleocaspid in SARS patients</title></titleInfo><name type="personal"><namePart type="given">YL</namePart><namePart type="family">Shi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ZY</namePart><namePart type="family">Wan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LH</namePart><namePart type="family">Li</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Shi YL, Wan ZY, Li LH et al. Antibody responses against SARS‐coronavirus and its nucleocaspid in SARS patients. J. Clin. Virol. 2004; 31: 66–8.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>66</start><end>8</end></extent></part><relatedItem type="host"><titleInfo><title>J. Clin. Virol.</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>66</start><end>8</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit13"><titleInfo><title>Coronavirus as a possible cause of severe acute respiratory syndrome</title></titleInfo><name type="personal"><namePart type="given">JSM</namePart><namePart type="family">Peiris</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ST</namePart><namePart type="family">Lai</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LLM</namePart><namePart type="family">Poon</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Peiris JSM, Lai ST, Poon LLM et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003; 361: 1319–25.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>361</number></detail><extent unit="pages"><start>1319</start><end>25</end></extent></part><relatedItem type="host"><titleInfo><title>Lancet</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>361</number></detail><extent unit="pages"><start>1319</start><end>25</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit14"><titleInfo><title>Antibody response and viraemia during the course of severe acute respiratory syndrome (SARS)‐associated coronavirus infection</title></titleInfo><name type="personal"><namePart type="given">WJ</namePart><namePart type="family">Chen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ZY</namePart><namePart type="family">Xu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JS</namePart><namePart type="family">Mu</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chen WJ, Xu ZY, Mu JS et al. Antibody response and viraemia during the course of severe acute respiratory syndrome (SARS)‐associated coronavirus infection. J. Med. Microbiol. 2004; 53: 435–8.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>435</start><end>8</end></extent></part><relatedItem type="host"><titleInfo><title>J. Med. Microbiol.</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>435</start><end>8</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit15"><titleInfo><title>Development of IFA method for detecting antibodies of SARS coronavirus</title></titleInfo><name type="personal"><namePart type="given">BY</namePart><namePart type="family">Si</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Yan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Yu</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Si BY, Yan B, Yu M. Development of IFA method for detecting antibodies of SARS coronavirus. Med. J. Chin. People's Liberat. Army 2003; 28: 699–700.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>699</start><end>700</end></extent></part><relatedItem type="host"><titleInfo><title>Med. J. Chin. People's Liberat. Army</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>699</start><end>700</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit16"><titleInfo><title>Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China</title></titleInfo><name type="corporate"><namePart>The Chinese SARS Molecular Epidemiology Consortium.</namePart></name><genre>journal-article</genre><note type="citation/reference">The Chinese SARS Molecular Epidemiology Consortium. Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China. Science 2004; 303: 1666–9.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>303</number></detail><extent unit="pages"><start>1666</start><end>9</end></extent></part><relatedItem type="host"><titleInfo><title>Science</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>303</number></detail><extent unit="pages"><start>1666</start><end>9</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit17"><titleInfo><title>Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus</title></titleInfo><name type="personal"><namePart type="given">PC</namePart><namePart type="family">Woo</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SK</namePart><namePart type="family">Lau</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">BH</namePart><namePart type="family">Wong</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Woo PC, Lau SK, Wong BH et al. Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus. Clin. Diagn. Lab. Immunol. 2004; 11: 665–8.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>665</start><end>8</end></extent></part><relatedItem type="host"><titleInfo><title>Clin. Diagn. Lab. Immunol.</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>665</start><end>8</end></extent></part></relatedItem></relatedItem><identifier type="istex">15DD49E0ED3C4B260E52012856E849161EB2D3A8</identifier><identifier type="ark">ark:/67375/WNG-JTPM1CPK-3</identifier><identifier type="DOI">10.1111/j.1440-1843.2006.00783.x</identifier><identifier type="ArticleID">RESP783</identifier><accessCondition type="use and reproduction" contentType="copyright">© Wiley. All rights reserved.</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Converted from (version ) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2019-11-16</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-JTPM1CPK-3/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000520 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000520 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:15DD49E0ED3C4B260E52012856E849161EB2D3A8
|texte= Longitudinal profile of antibodies against SARS‐coronavirus in SARS patients and their clinical significance
}}
| This area was generated with Dilib version V0.6.33. |  |